Selected article for: "plasmon resonance and Surface plasmon resonance"
Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future
  • Document date: 2017_3_28
    • ID: 0fegsm1v_66
    Snippet: Antibody characterization involves peptide mapping, glycan characterization analysis, purification, fragmentation of antibody pharmacokinetics, and quality assurance for many applications in basic research (Roth et al., 2012) . The scFv antibody is usually characterized by affinity, isotype, cross binding, phage-ELISA, and immunoblot. Biochemical characterization includes the expression of scFv antibody in a soluble form in infected E. coli cells.....
    Document: Antibody characterization involves peptide mapping, glycan characterization analysis, purification, fragmentation of antibody pharmacokinetics, and quality assurance for many applications in basic research (Roth et al., 2012) . The scFv antibody is usually characterized by affinity, isotype, cross binding, phage-ELISA, and immunoblot. Biochemical characterization includes the expression of scFv antibody in a soluble form in infected E. coli cells. In addition, further characterization is carried out by immunofluorescence antibody test (IFAT), mass spectrometry, sequencing and indirect immunofluorescence (IFI) assays, cytotoxicity analysis, surface plasmon resonance, and NMR spectroscopy Yuasa et al., 2014; Levenhagen et al., 2015) .

    Search related documents:
    Co phrase search for related documents
    • indirect immunofluorescence and plasmon resonance: 1
    • indirect immunofluorescence and quality assurance: 1
    • indirect immunofluorescence and soluble form: 1
    • indirect immunofluorescence and surface plasmon resonance: 1
    • mass spectrometry and NMR spectroscopy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
    • mass spectrometry and peptide mapping: 1, 2, 3, 4, 5
    • mass spectrometry and plasmon resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • mass spectrometry and scfv antibody: 1
    • mass spectrometry and soluble form: 1, 2
    • mass spectrometry and surface plasmon resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • NMR spectroscopy and peptide mapping: 1
    • NMR spectroscopy and plasmon resonance: 1, 2, 3
    • NMR spectroscopy and soluble form: 1
    • NMR spectroscopy and surface plasmon resonance: 1, 2, 3
    • peptide mapping and plasmon resonance: 1, 2, 3, 4
    • peptide mapping and surface plasmon resonance: 1, 2, 3, 4
    • plasmon resonance and scfv antibody: 1, 2, 3
    • plasmon resonance and surface plasmon resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
    • plasmon resonance and usually characterize: 1